



## OPEN ACCESS

EDITED AND REVIEWED BY  
Chun Xu,  
The University of Sydney, Australia

\*CORRESPONDENCE  
Zhihua Chen,  
✉ zhihuachen@zju.edu.cn  
Huaqiong Huang,  
✉ zr\_hhq@zju.edu.cn

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share last authorship

RECEIVED 17 July 2025  
ACCEPTED 25 July 2025  
PUBLISHED 07 August 2025

CITATION  
Liu Z, Fang D, Chen K, Dong L, Huang H and Chen Z (2025) Correction: Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury. *Front. Pharmacol.* 16:1667879. doi: 10.3389/fphar.2025.1667879

COPYRIGHT  
© 2025 Liu, Fang, Chen, Dong, Huang and Chen. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

# Correction: Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury

Zhengyuan Liu<sup>†</sup>, Danruo Fang<sup>†</sup>, Kaijun Chen, Lingling Dong, Huaqiong Huang<sup>\*\*</sup> and Zhihua Chen<sup>\*\*†</sup>

Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

## KEYWORDS

acute lung injury, mitophagy inducer, TJ0113, NF- $\kappa$ B, NLRP3 inflammasome

## A Correction on Novel mitophagy inducer TJ0113 alleviates pulmonary inflammation during acute lung injury

by Liu Z, Fang D, Chen K, Dong L, Huang H and Chen Z (2025). *Front. Pharmacol.* 16:1590458. doi: 10.3389/fphar.2025.1590458

In the published article, there was an error in the description of the regulatory status of TJ0113. The article incorrectly stated that TJ0113 had received clinical approval for Alport syndrome from both the China National Medical Products Administration and the U.S. Food and Drug Administration. In fact, TJ0113 has only been approved to initiate a Phase I clinical trial in China (CTR20232426) for the treatment of Alport syndrome, and has not received clinical approval for this indication from the U.S. Food and Drug Administration.

A correction has been made to **Abstract**, Paragraph 1. This sentence previously stated: “TJ0113 has received clinical approval for Alport syndrome from both the China National Medical Products Administration and the U.S. Food and Drug Administration.”

The corrected sentence appears below:

“TJ0113 has been approved to initiate a Phase I clinical trial for Alport syndrome and a Phase II trial for Parkinson’s disease in China.”

A correction has been made to **Discussion**, Paragraph 2. This sentence previously stated:

“Notably, TJ0113 has received clinical approval for the treatment of Alport syndrome from both the China National Medical Products Administration and the U.S. Food and Drug Administration, and is currently undergoing further clinical evaluation for Parkinson’s disease and depression (ClinicalTrials.gov ID: NCT06832540, NCT06596005; CTR20232426).”

The corrected sentence appears below:

“Notably, TJ0113 has been approved to initiate clinical trial for Alport syndrome, Parkinson’s disease and depression in China (CTR20232426, CTR20243324, CTR20252210).”

The original article has been updated.

## Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.